Clinical results for Episealer® accepted for presentation at the 19th ESSKA Congress
Episurf Medical (Nasdaq: EPIS B) today announces that an abstract with results from the European multicentre study with 24 months’ follow up of 75 Episealer® Knee patients has been accepted for presentation at the upcoming 19th ESSKA congress. The abstract, “Mini-metal implants – 2 year detailed cohort analysis of a patient specific implant“ is authored by Associate Professor Tim Spalding, University Hospitals Coventry and Warwickshire NHS Trust, UK.
ESSKA (European Society for Sports Traumatology, Knee Surgery and Arthroscopy) is a European organisation focusing on degenerative joint diseases and sports medicine. The 19th ESSKA Congress will be held online on 11-15 May 2021.
The abstract reports on the clinical outcome of 75 patients from 9 clinics in 6 European countries, undergoing treatment with the individualised knee implant Episealer® for treatment of isolated chondral and osteochondral defects in the knee.
“We are pleased that this scientific abstract with clinical results from the European multicentre study of Episealer® patients has been accepted for presentation at this important congress. This shows that there is a genuine interest in our technology” says Pål Ryfors, CEO Episurf Medical.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] => <p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><strong><span style="font-size:10pt">About Episurf Medical</span></strong></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></p>
[HtmlContact:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><strong><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">For more information, please contact:</span></strong></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Pål Ryfors, CEO, Episurf Medical<br /></span><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">Tel:</span><span style="font-size: 10pt;">+46 (0) 709 62 36 69<br /></span><span style="font-size: 10pt;">Email: </span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></p>
[HtmlTitle:protected] => <h1 style="line-height:120%"><span style="font-family:arial,helvetica,sans-serif"><strong>Clinical results for Episealer® accepted for presentation at the 19th ESSKA Congress </strong></span></h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] =>
[Body:protected] => Episurf Medical (Nasdaq: EPIS B) today announces that an abstract with results from the European multicentre study with 24 months’ follow up of 75 Episealer® Knee patients has been accepted for presentation at the upcoming 19[th] ESSKA congress. The abstract, “Mini-metal implants - 2 year detailed cohort analysis of a patient specific implant“ is authored by Associate Professor Tim Spalding, University Hospitals Coventry and Warwickshire NHS Trust, UK.
ESSKA (European Society for Sports Traumatology, Knee Surgery and Arthroscopy) is a European organisation focusing on degenerative joint diseases and sports medicine. The 19[th] ESSKA Congress will be held online on 11-15 May 2021.
The abstract reports on the clinical outcome of 75 patients from 9 clinics in 6 European countries, undergoing treatment with the individualised knee implant Episealer® for treatment of isolated chondral and osteochondral defects in the knee.
“We are pleased that this scientific abstract with clinical results from the European multicentre study of Episealer® patients has been accepted for presentation at this important congress. This shows that there is a genuine interest in our technology” says Pål Ryfors, CEO Episurf Medical.
[HtmlBody:protected] => <p style="margin-bottom: 11px; font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="line-height:107%"><span style="line-height:107%">Episurf Medical (Nasdaq: EPIS B) today announces that an abstract with results from the European multicentre study with 24 months’ follow up of 75 Episealer</span><span style="line-height:107%">® Knee patients has been accepted for p</span><span style="line-height:107%">resentation at the upcoming 19<sup>th</sup> ESSKA congress. The abstract, </span><em><span style="line-height:107%">“Mini-metal implants - 2 year detailed cohort analysis of a patient specific implant“ </span></em><span style="line-height:107%">is authored by</span> <span style="line-height:107%">Associate Professor Tim Spalding, University Hospitals Coventry and Warwickshire NHS Trust, UK. </span></span></p>
<p style="margin-bottom: 11px; font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="line-height:107%"><span style="line-height:107%">ESSKA (European Society for Sports Traumatology, Knee Surgery and Arthroscopy) is a European organisation focusing on degenerative joint diseases and sports medicine. The 19<sup>th</sup> ESSKA Congress will be held online on 11-15 May 2021.</span></span></p>
<p style="margin-bottom: 11px; font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="line-height:107%"><span style="line-height:107%">The abstract reports on the clinical outcome of 75 patients from 9 clinics in 6 European countries, u</span><span style="line-height:107%">ndergoing treatment with the individualised knee implant Episealer® for treatment of isolated chondral and osteochondral defects in the knee.</span></span></p>
<p style="margin-bottom: 11px; font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="line-height:107%"><span style="line-height:107%">“We are pleased that this scientific abstract with clinical results from the European multicentre study of Episealer® patients has been accepted for presentation at this important congress. This shows that there is a genuine interest in our technology” says Pål Ryfors, CEO Episurf Medical.</span></span></p>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => LinkedIn
[Name:protected] => LinkedIn
[Value:protected] => 12311
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 9307
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] => About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
[Contact:protected] => For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
[2] => Pål Ryfors
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/3310489/1389767.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => Clinical results for Episealer® accepted for presentation at the 19th ESSKA Congress
[Description:protected] => Clinical results for Episealer® accepted for presentation at the 19th ESSKA Congress
[CreateDate:protected] => 2021-03-19T08:45:09.247Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 3923339
[EncryptedId:protected] => 7BB05944A8C89CEB
[IsRegulatory:protected] =>
[PublishDate:protected] => 2021-03-19T08:45:00Z
[LastChangeDate:protected] => 2021-03-19T08:45:09.2Z
[Title:protected] => Clinical results for Episealer® accepted for presentation at the 19th ESSKA Congress
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => PRM
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/clinical-results-for-episealer--accepted-for-presentation-at-the-19th-esska-congress,c3310489
[LanguageVersions:protected] => Array
(
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)